Biogen Inc. (BIIB)
| Market Cap | 20.45B |
| Revenue (ttm) | 9.68B |
| Net Income (ttm) | 1.63B |
| Shares Out | 146.37M |
| EPS (ttm) | 11.18 |
| PE Ratio | 12.50 |
| Forward PE | 8.89 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 831,121 |
| Open | 137.19 |
| Previous Close | 137.08 |
| Day's Range | 137.66 - 140.46 |
| 52-Week Range | 128.51 - 238.00 |
| Beta | -0.08 |
| Analysts | Buy |
| Price Target | 220.50 (+57.83%) |
| Earnings Date | Feb 12, 2025 |
About BIIB
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar r... [Read more]
Financial Performance
In 2024, Biogen's revenue was $9.68 billion, a decrease of -1.62% compared to the previous year's $9.84 billion. Earnings were $1.63 billion, an increase of 40.57%.
Financial StatementsAnalyst Forecast
According to 27 analysts, the average rating for BIIB stock is "Buy." The 12-month stock price forecast is $220.5, which is an increase of 57.83% from the latest price.
News
Stoke Therapeutics and Biogen in pact for treatment for severe form of childhood epilepsy
Stoke will receive $165 million upfront and may get up to $385 million in milestone payments.
Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments
CAMBRIDGE, Mass. & BEDFORD, Mass.--(BUSINESS WIRE)--Biogen Inc. (Nasdaq: BIIB) and Stoke Therapeutics, Inc. (Nasdaq: STOK) today announced a collaboration for the development and commercialization of ...
Biogen Q4 Earnings Review: Why I'm Calling Time On This 'Powder Puff' Pharma
Biogen's Q4 2024 earnings showed slight revenue growth but Wall Street remains unimpressed due to weak guidance and declining key drug franchises. Leqembi's commercial performance is disappointing, mi...
Leqembi And Skyclarys Expected To Drive Biogen's Future Growth: Analysts
On Wednesday, Biogen Inc BIIB reported fourth-quarter adjusted EPS of $3.44, up 17%, beating the consensus of $3.35.
Biogen Analysts Lower Their Forecasts After Q4 Results
Biogen Inc BIIB reported better-than-expected earnings for its fourth quarter on Wednesday.
Biogen Delivers Q4 Beat, Analyst Focuses On Leqembi Expansion, 2025 Outlook
On Wednesday, Biogen Inc BIIB reported fourth-quarter adjusted EPS of $3.44, up 17%, beating the consensus of $3.35.
Biogen Inc. (BIIB) Q4 2024 Earnings Call Transcript
Biogen Inc. (NASDAQ:BIIB) Q4 2024 Earnings Conference Call February 12, 2025 8:30 AM ET Company Participants Tim Power - Head of IR Chris Viehbacher - President and CEO Priya Singhal - Head of Develo...
Biogen's stock hit by soft guidance and a decline in sales of MS drugs
Sales of an Alzheimer's disease treatment were better than expected, but that and a quarterly beat wasn't enough to offset below-consensus EPS outlook.
Biogen beats estimates on cost cuts and new drugs like Leqembi, but profit outlook falls short
Biogen posted fourth-quarter revenue and profit that topped expectations as its cost cuts showed progress and new products, including its breakthrough Alzheimer's treatment Leqembi, saw growth. The b...
Drugmaker Biogen forecasts 2025 profit below expectations
Biogen forecast 2025 profit below Wall Street expectations on Wednesday, hurt by a strong dollar and fierce competition for its drugs to treat multiple sclerosis.
Biogen Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
Biogen Inc. BIIB will release its fourth-quarter financial results, before the opening bell, on Wednesday, Feb. 12, 2025.
Europe to review safety data for Eisai-Biogen Alzheimer's drug
The European Commission has requested its medicines regulator to consider safety information on Eisai and Biogen's Alzheimer's drug Leqembi, the agency said on Friday.
Update on Regulatory Review of Lecanemab for Early Alzheimer's Disease in the European Union
TOKYO and CAMBRIDGE, Mass., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massach...
Sage rejects Biogen's $469 million takeover offer
Sage Therapeutics said on Monday that its board has unanimously rejected the takeover offer it received from Biogen.
US FDA OKs monthly maintenance dosing for Eisai/Biogen's Alzheimer's drug
The U.S. Food and Drug Administration has approved monthly maintenance dosing for Japan's Eisai and partner Biogen's Alzheimer's drug Leqembi, the companies said on Monday.
FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease
Once every four weeks maintenance dosing may be easier for patients and care partners to continue treatment Alzheimer's disease progression does not stop after plaque clearance; ongoing treatment with...
FDA and EMA Accept Applications for Higher Dose Regimen of Nusinersen in SMA
Applications are based on data from the DEVOTE study, which demonstrate the potential for the investigational higher dose regimen of nusinersen to advance the treatment of SMA Applications are based o...
Genetic Toxicology Testing Market Research 2024-2034: Increased R&D Activities, Strategic Collaborations, and a Focus on Personalized Therapy Boosts Growth
The Genetic Toxicology Testing market is expected to rise due to rising genetic disease incidence, advancements in genetic toxicology testing technologies, increased R&D activities, strategic collabor...
Biogen Inc. (BIIB) J.P. Morgan 43rd Annual Healthcare Conference (Transcript)
Biogen Inc. (BIIB) J.P. Morgan 43rd Annual Healthcare Conference (Transcript)
Biogen CEO sees no burning need for more acquisitions
Biogen expects revenue from new launches to exceed its current sales by 2028 and does not feel the need to chase additional business development deals, the company's CEO said.
FDA Accepts LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease
LEQEMBI is the only FDA-approved anti-amyloid therapy that potentially could offer the convenience of a subcutaneous injection with at-home administration option LEQEMBI is the only FDA-approved anti-...
Sage Therapeutics Stock Soars as Biogen Makes Unsolicited Takeover Bid
Sage Therapeutics (SAGE) shares soared nearly 40% Monday on news Biogen (BIIB) is offering to buy the rest of the Sage stock it doesn't already own for $7.22 per share.
Sage Therapeutics Stock Rockets 35% Higher After Takeover Bid From Biogen
The biopharmaceutical company says its board of directors will now review and evaluate the offer from Biogen.
Sage Therapeutics Confirms Receipt of Unsolicited Nonbinding Acquisition Proposal from Biogen
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE) (“The Company”), today confirmed that Biogen Inc. (Nasdaq: BIIB) (“Biogen”) has submitted to the Company an unsolicited, nonbi...
Biogen proposes to buy remaining stake in Sage in $442 million deal
Drugmaker Biogen will buy all outstanding shares of Sage Therapeutics that it does not already own for $7.22 apiece, a filing showed on Friday, sending the latter's stock up 34% in extended trade.